Bradley Pharmaceuticals Issues Impressive Goal: 400,000 New Prescriptions for Key Promoted Brands in 2001

Apr 20, 2001, 01:00 ET from Bradley Pharmaceuticals, Inc.

    FAIRFIELD, N.J., April 20 /PRNewswire/ --
 Bradley Pharmaceuticals, Inc. (Nasdaq: BPRX) continues to report significant
 New Prescription increases for First Quarter 2001.  These successful results
 are based on bold initiatives first taken in early 2000 to refocus marketing
 and selling resources on dermatological, nutritional and gastroenterological
 key brands with the greatest growth and profit potential.  Now, the management
 team has announced plans to build on the momentum generated by this dynamic
 new approach.
     In 2000, the first full year that Bradley implemented its new strategy,
 the Company realized approximately 173,000 New Prescriptions for the newly
 designated key promoted brands.  These key promoted brands are: Carmol(R) 40,
 a potent, yet gentle, tissue softener; Glutofac(R)-ZX, a prescription
 multivitamin and multimineral; and Pamine(R), an antispasmodic/
 anticholinergic for relief of such GI/hypermotility symptoms as bloating,
 diarrhea, and cramps.
     The Goal for the Year 2001 is 400,000 New Prescriptions, accounted for by
 the Company's key promoted brands.
 
   First Quarter 2001 results are very encouraging, reaching New Prescription
   heights and trending higher every month.  Compared to First Quarter 2000:
 
           Carmol(R) 40 New Prescriptions increased by 197%;
           Glutofac(R)-ZX New Prescriptions increased by 71%;
           Pamine(R) New Prescriptions increased by 73%.
 
     As Daniel Glassman, President & CEO, points out, "New Prescriptions are
 considered the sales and profit indicators of Bradley Pharmaceuticals.  The
 number of New Prescriptions written by physicians, and filled by pharmacists,
 is generally accepted within the pharmaceutical industry as predictors of
 future sales of a company's products.  In essence, New Prescription trends
 usually forecast future sales for particular brands.  The New Prescription
 results, thus far in 2001, are a very strong indicator that we are well on our
 way to our Goal."
 
     Bradley Pharmaceuticals markets prescription and ethically-promoted
 non-prescription drugs throughout the US and in 31 international markets.
 Bradley delivers gastroenterology, nutritional and respiratory brands through
 its Kenwood Therapeutics division, and dermatology brands through its Doak
 Dermatologics subsidiary.  The Company remains focused on core strengths of
 marketing, sales and financial control, and has achieved success by targeting
 unfilled marketing opportunities and introducing product line extensions to
 fill unmet needs.
 
     Important announcement:  First Quarter 2001 Earnings will be released on
 Thursday, April 26, 2001 at 9 a.m. EST.
 
     Bradley Pharmaceuticals common stock is quoted on the NASDAQ market under
 the symbol BPRX.
 
     Please visit Bradley Pharmaceuticals' web site at:
 http://www.bradpharm.com.
 
     This release may contain forward-looking statements that reflect
 management's current views of future events and operations.  These
 forward-looking statements are based on assumptions and external factors,
 including assumptions relating to regulatory action, capital requirements and
 competing products.  The occurrence of actual events may differ materially due
 to a variety of factors, including customer acceptance and competitive
 pressures.
 
 

SOURCE Bradley Pharmaceuticals, Inc.
    FAIRFIELD, N.J., April 20 /PRNewswire/ --
 Bradley Pharmaceuticals, Inc. (Nasdaq: BPRX) continues to report significant
 New Prescription increases for First Quarter 2001.  These successful results
 are based on bold initiatives first taken in early 2000 to refocus marketing
 and selling resources on dermatological, nutritional and gastroenterological
 key brands with the greatest growth and profit potential.  Now, the management
 team has announced plans to build on the momentum generated by this dynamic
 new approach.
     In 2000, the first full year that Bradley implemented its new strategy,
 the Company realized approximately 173,000 New Prescriptions for the newly
 designated key promoted brands.  These key promoted brands are: Carmol(R) 40,
 a potent, yet gentle, tissue softener; Glutofac(R)-ZX, a prescription
 multivitamin and multimineral; and Pamine(R), an antispasmodic/
 anticholinergic for relief of such GI/hypermotility symptoms as bloating,
 diarrhea, and cramps.
     The Goal for the Year 2001 is 400,000 New Prescriptions, accounted for by
 the Company's key promoted brands.
 
   First Quarter 2001 results are very encouraging, reaching New Prescription
   heights and trending higher every month.  Compared to First Quarter 2000:
 
           Carmol(R) 40 New Prescriptions increased by 197%;
           Glutofac(R)-ZX New Prescriptions increased by 71%;
           Pamine(R) New Prescriptions increased by 73%.
 
     As Daniel Glassman, President & CEO, points out, "New Prescriptions are
 considered the sales and profit indicators of Bradley Pharmaceuticals.  The
 number of New Prescriptions written by physicians, and filled by pharmacists,
 is generally accepted within the pharmaceutical industry as predictors of
 future sales of a company's products.  In essence, New Prescription trends
 usually forecast future sales for particular brands.  The New Prescription
 results, thus far in 2001, are a very strong indicator that we are well on our
 way to our Goal."
 
     Bradley Pharmaceuticals markets prescription and ethically-promoted
 non-prescription drugs throughout the US and in 31 international markets.
 Bradley delivers gastroenterology, nutritional and respiratory brands through
 its Kenwood Therapeutics division, and dermatology brands through its Doak
 Dermatologics subsidiary.  The Company remains focused on core strengths of
 marketing, sales and financial control, and has achieved success by targeting
 unfilled marketing opportunities and introducing product line extensions to
 fill unmet needs.
 
     Important announcement:  First Quarter 2001 Earnings will be released on
 Thursday, April 26, 2001 at 9 a.m. EST.
 
     Bradley Pharmaceuticals common stock is quoted on the NASDAQ market under
 the symbol BPRX.
 
     Please visit Bradley Pharmaceuticals' web site at:
 http://www.bradpharm.com.
 
     This release may contain forward-looking statements that reflect
 management's current views of future events and operations.  These
 forward-looking statements are based on assumptions and external factors,
 including assumptions relating to regulatory action, capital requirements and
 competing products.  The occurrence of actual events may differ materially due
 to a variety of factors, including customer acceptance and competitive
 pressures.
 
 SOURCE  Bradley Pharmaceuticals, Inc.